Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis

Surgery Today
Keigo SekiharaMasahiro Tsuboi

Abstract

Lung cancer in patients with idiopathic pulmonary fibrosis (IPF) is associated with a poor prognosis and postoperative acute exacerbation (AE) of IPF is a fatal complication. Studies have shown that perioperative pirfenidone treatment (PPT) may reduce the incidence of AE-IPF. We evaluated the efficacy of PPT in preventing AE-IPF and improving overall survival. The subjects of this study were 56 patients with IPF who underwent resection of lung cancer in our hospital between January, 2011 and September, 2016. Pirfenidone was administered to patients from 4 weeks before the operation and continued for longer periods. Thirty-six patients received PPT and their outcome was compared with that of the other 20 patients who did not. There were no differences in age, gender, smoking history, respiratory function, or surgical procedures between the groups. AE-IPF developed in three patients (8%) in the PPT group and four (20%) patients in the non-PPT group, without a significant difference between the groups. The interval was significantly longer in the PPT group (p = 0.03). PPT reduced postoperative mortality significantly (p = 0.04). Although perioperative pirfenidone treatment did not obviously prevent postoperative AE-IPF, it may red...Continue Reading

References

Jan 28, 1998·American Journal of Respiratory and Critical Care Medicine·J A BjorakerK P Offord
Jan 5, 2000·American Journal of Respiratory and Critical Care Medicine·R HubbardJ Britton
Sep 5, 2002·Journal of Surgical Oncology·Hidenori KawasakiYutaka Nishiwaki
Jun 28, 2003·The Journal of Thoracic and Cardiovascular Surgery·P KumarG Ladas
Oct 21, 2003·The Journal of Thoracic and Cardiovascular Surgery·Masako ChiyoTakehiko Fujisawa
Jan 3, 2006·The European Respiratory Journal·D S KimT Colby
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiko AndoMasahiro Fukuoka
Jun 14, 2006·Thorax·Robin M RuddUNKNOWN Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society
Nov 14, 2007·Chest·Robert HyzyFernando Martinez
Nov 26, 2008·The Journal of Thoracic and Cardiovascular Surgery·Atsushi WatanabeTohru Mawatari
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
May 17, 2011·Lancet·Paul W NobleUNKNOWN CAPACITY Study Group
May 31, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hirotsugu KenmotsuNobuyuki Yamamoto
Jun 4, 2011·Pulmonary Medicine·Atsushi WatanabeTetsuya Higami
Nov 26, 2013·The Journal of Thoracic and Cardiovascular Surgery·Toshihiko SatoUNKNOWN Japanese Association for Chest Surgery
May 20, 2014·The New England Journal of Medicine·Talmadge E KingUNKNOWN ASCEND Study Group
Dec 3, 2014·The Journal of Thoracic and Cardiovascular Surgery·Toshihiko SatoUNKNOWN Japanese Association for Chest Surgery
Aug 23, 2016·The Annals of Thoracic Surgery·Takekazu IwataIchiro Yoshino
Dec 23, 2017·Interactive Cardiovascular and Thoracic Surgery·Keigo SekiharaMasahiro Tsuboi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.